Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane

Definitions

• This invention relates to novel estratrienes.
• the estrogenic effects of 3,17-dihydroxy-1,3,5(10)-estratrienes and esters and ethers thereof are known.
• the compounds of this invention exhibit high vaginotropic but only weak uterotropic activity.
• 18-Hydroxyestrone and 18-hydroxyestrone diacetate are know [Baldwin et al., J. Chem. Soc. (C) 1968, 2283 ].
• this invention relates to 3,17,18-trihydroxy-1,3,5(10)-estratriene and esters and ethers thereof of the general Formula I ##SPC2##
• R 1 , R 2 , R 3 which can be alike or different, are a hydrogen atom, acyl, alkyl, cycloalkyl, or an oxygen-containing saturated heterocyclic group, and
• R 4 is a hydrogen atom or a substituted or unsubstituted saturated or unsaturated hydrocarbon group.
• this invention relates to pharmaceutical compositions comprising a vaginotropic effective amount per unit dosage of compound of this invention in admixture with a pharmaceutically acceptable carrier.
• this invention relates to a process for the production of the compounds of this invention.
• Suitable acyl groups are those of any physiologically acceptable acid including phosphoric, sulfuric, sulfonic and carboxylic acids.
• Preferred acyl groups are those of hydrocarbon carboxylic acids of 1-15 carbon atoms, including those of the aliphatic, cycloaliphatic, aromatic and aromatic-aliphatic series. Equivalents of these are those of the heterocyclic series and those which are unsaturated and/or polybasic and/or substituted in the usual manner, e.g., by alkyl, hydroxy, alkoxy, oxo, or amino groups, or halogen atoms.
• suitable carboxylic acids are alkanoic of 1-15, preferably 2-8, carbon atoms, e.g., formic acid, acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, isovaleric acid, caproic acid, enanthic acid, caprylic acid, pelargonic acid, undecylic acid, lauric acid, tridecylic acid, myristic acid, trimethylacetic acid, diethylacetic acid, tert.-butylacetic acid, and cycloalkylalkanoic acids wherein cycloalkyl and alkanoic are as defined herein, e.g., cyclopentylacetic acid, cyclohexylacetic acid, cyclohexanecarboxylic acid and arylcarbocyclic carboxylic and arylcarbocyclicalkanoic acids of 7-15, preferably 7-12 carbon atoms, e.g., benzoic and
• Equivalents of these acids are, e.g., phenoxyacetic acid, mono-, di-, and trichloroacetic acid, aminoacetic acid, diethylaminoacetic acid, piperidinoacetic acid, morpholinoacetic acid, lactic acid, succinic acid, adipic acid, malonic acid, nicotinic acid, isonicotinic acid, and furan-2-carboxylic acid.
• Preferred alkyl are lower alkyl of 1- 5 carbon atoms, which can be branched in the usual manner. Especially preferred are methyl and ethyl. Equivalents are those substituted in the usual manner, e.g., halogen, preferably by Cl, or alkoxy of 1-4 carbon atoms, e.g., methoxy.
• cycloalkyl examples include those of 3-8 ring carbon atoms, e.g., cyclopropyl, cyclopentyl, cyclohexyl and cycloheptyl and the corresponding rings bearing, e.g., 1-3 alkyl, preferably methyl groups. Cyclopentyl is preferred.
• a saturated oxygen-containing heterocyclic group is tetrahydropyranyl, which is preferred.
• Equivalents are any other such groups derived from heterocycles with at least one oxygen atom in the ring and perhydrogenated in the oxygen-containing ring, e.g., tetrahydrofuryl.
• hydrocarbon groups are saturated and monounsaturated hydrocarbons of up to 6 carbon atoms, viz., alkyl, alkenyl and alkinyl, e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, vinyl, ethinyl and propenyl.
• Equivalents are di-unsubstituted groups, e.g., butadienyl, and butadinynyl and the corresponding hydrocarbon groups bearing the usual, suitable substituents, e.g., halogen, preferably chloro.
• Preferred hydrocarbon and substituted hydrocarbon groups are ethinyl and chloroethinyl, respectively.
• Preferred classes of compounds of this invention are those wherein:
• R 1 , R 2 and R 3 which are alike or different, are hydrogen atoms, alkyl of 1- 4 carbon atoms, preferably methyl, alkanoyl of 2-8 carbon atoms, preferably acetoxy, and R 4 is a hydrogen atom or, when R 3 is a hydrogen atom, ethinyl;
• the compounds of this invention have a favorable dissociated pharmacological activity, viz., strongly vaginotropic and weakly uterotropic activity, and are thus suitable for the treatment of estrogen deficiency indications where an estrogenic effect on the vaginal epithelium is desired, but an estrogenic effect on the uterus is to be avoided, if at all possible, e.g., in the treatment of estrogenic deficiency in postmenopausal females.
• the compounds are useful to delay the aging syndrome in such females, e.g., osteoporosis; depressive mood, peripheric circulatory disorders, cardiac diseases and senile otosclerosis.
• This advantageous estrogenic dissociation can be shown, for example, in the sialic acid test on mice.
• the sialic acid test is conducted as follows:
• the compounds of this invention have a high dissociation quotient far exceeding that of the standard compounds, as shown in Table 1, using as examples 3,18-diacetoxy-17 ⁇ -ethinyl-1,3,5(10)-estratrien-17 ⁇ -ol (I) and 3,18-diacetoxy-1,3,5(10)-estratrien-17 ⁇ -ol (II), compared with the conventional estrogens 17 ⁇ -ethinyl-1,3,5(10)-estratriene-3,17 ⁇ -diol (III) and 1,3,5(10)-estratriene-3,17 ⁇ -diol (IV).
• This invention also relates to pharmaceutical compositions comprising an estratriene of the general Formula I in admixture with a pharmaceutically acceptable carrier.
• compositions are produced in the usual manner by formulating the effective agents into the desired forms of application, e.g., tablets, dragees, capsules, oral or injectable solutions, employing the usual vehicles, diluents, flavor-ameliorating agents, etc. customary in galenic pharmacy.
• a tablet preferably contains 0.01 - 10 mg.
• solutions for parenteral administration preferably contain 0.1 - 20 mg./ml. of solution.
• the dosage of the medicinal agents of this invention can vary with the type of administration and the respectively selected compound. Moreover, the dosage can vary from the patient.
• the compounds of the present invention are administered at a dosage level which can achieve the desired results without causing any disadvantageous or deleterious side effects.
• the compounds are administered, for example, at a dosage level ranging from approximately 0.02 mg. to about 20 mg., although modifications can be made under certain circumstances, so that a dosage level of more than 20 mg., for example up to 50 mg., is employed.
• a dosage level in the range of about 0.05 mg. to approximately 5 mg. is preferred.
• R 1 and R 2 have the values given above and optionally thereafter splitting off any R 1 or R 2 ether or acyl groups or esterifying any or all free hydroxy groups.
• the reduction of the 17-keto group can be effected with hydrogen under pressure (for example 50 atmospheres gauge) in the presence of a conventional catalyst, such as, for example, Raney nickel in benzene, at room temperature.
• a conventional catalyst such as, for example, Raney nickel in benzene
• the hydrogen atoms also can be transferred to the 17-keto group from metal hydrides.
• Especially suitable as hydrogen donors are the complex hydrides, e.g., sodium hydridoborate, lithium hydridoaluminate, sodium hydridotrimethoxoborate and lithium hydrido-tri-tert.-butoxoaluminate.
• R 4 is the organic group of the organometallic compound, e.g., an alkylmagnesium halide, such as, for example, methylmagnesium bromide or iodide, an alkenylmagnesium and/or alkenylzinc halide, e.g., vinylmagnesium bromide or allylmagnesium bromide, an alkinylmagnesium halide, such as ethinylmagnesium bromide, propinylmagnesium bromide, or propinylzinc bromide, or an alkali metal acetylide, e.g., potassium acetylide.
• an alkylmagnesium halide such as, for example, methylmagnesium bromide or iodide
• an alkenylmagnesium and/or alkenylzinc halide e.g., vinylmagnesium bromide or allylmagnesium bromide
• the organometallic compound employed as the reducing agent can also be formed in situ and reacted with the 17-ketone of Formula II.
• the ketone is treated, in a suitable solvent, with an alkine, chloroalkine, or alkadiyne and an alkali metal, preferably in the presence of a tertiary alcohol or ammonia, optionally under elevated pressure.
• Free hydroxy groups can subsequently be esterified or etherified. Esterified or etherified hydroxy groups can be converted into the hydroxy groups.
• the acylation in the 3- and 18-positions is conducted preferably with pyridine and the selected acid anhydride at room temperature.
• suitable alkylating compounds preferably diazomethane, dialkyl sulfates, cycloalkyl halogenides and dihydropyran.
• the steroid is treated, for example, with an acid anhydride in the presence of a strong acid, e.g., p-toluenesulfonic acid, HClO 4 , or pyridine/acid anhydride under heating.
• a strong acid e.g., p-toluenesulfonic acid, HClO 4 , or pyridine/acid anhydride under heating.
• the last-mentioned methods can also be utilized to convert the free trihydroxy compounds directly to the triacylates thereof.
• 3,18-Diesters and 3,18-diethers can be converted into the corresponding 17-tetrahydropyranyl ethers with dihydropyran in the presence of a strong acid, such as, for example, p-toluenesulfonic acid.
• a strong acid such as, for example, p-toluenesulfonic acid.
• the etherification of the 17,18-OH-groups in the compounds of this invention containing an alkyl residue is preferably carried out with alkyl halogenides, e.g., methyl iodide, under gentle conditions, for example, in the presence of Ag 2 O in dimethylformamide, or after the preparation of the alkali metal alcoholates, in dimethylformamide with molar equivalent amounts of sodium hydride and subsequent reaction with dimethyl sulfate.
• alkyl halogenides e.g., methyl iodide
• the free 3-OH-group and the 18-OH-group can be liberated from 3,18-diacyl-17-tetrahydropyranyl derivatives by alkaline saponification.
• the ether splitting step is conducted according to methods known per se. For example, suitable methods are splitting with pyridine hydrochloride or pyridine/concentrated hydrochloric acid at an elevated temperature (180°-220° C.) or with hydrohalic acids in the presence of lower caboxylic acids at temperatures below 150° C.
• suitable methods are splitting with pyridine hydrochloride or pyridine/concentrated hydrochloric acid at an elevated temperature (180°-220° C.) or with hydrohalic acids in the presence of lower caboxylic acids at temperatures below 150° C.
• the splitting of tetrahydropyranyl ethers occurs under gentle conditions by the addition of acid.
• the starting compounds suitable for the preparation of the compounds of this invention are the known 18-hydroxyestrone and 18-hydroxyestrone diacetate.
• Other starting compounds can be produced analogously to processes known to persons skilled in the art.
• a solution of 900 mg. of 18-hydroxyestrone in 45 ml. of absolute benzene is combined with 1.35 ml. of distilled dihydropyran and 10 mg. of p-toluenesulfonic acid.
• the solution is agitated for 1.5 hours at room temperature, then washed to neutrality with a sodium bicarbonate solution and water, dried, and evaporated, thus obtaining 850 mg. of 3,18-bis(tetrahydropyranyloxy)-1,3,5(10)-estratrien-17-one as a crude product.
• a solution of 400 mg. of 17 ⁇ -ethinyl-1,3,5(10)-estratriene-3,17 ⁇ ,18-triol in 3 ml. of pyridine is mixed with 1.5 ml. of acetic anhydride and allowed to stand for 5 hours at room temperature. The mixture is then stirred into ice water, the precipitate is filtered off and taken up in ether. After drying and evaporation, the mixture is purified by chromatography on SiO 2 , thus obtaining 150 mg. of 3,18-diacetoxy-17 ⁇ -ethinyl-1,3,5(10)-estratrien-17 ⁇ -ol in the form of a foam.
• the organic phase is washed neutral with NH 4 Cl solution and water, dried, and evaporated, and the residue (1.5 g.) is dissolved in 5 ml. of pyridine and heated with 5 ml. of enanthic anhydride for 2 hours to 50° C. Thereafter, 25 ml. of water is added under agitation and cooling. After 1 hour of agitation, the mixture is taken up in ether.
• the organic phase is washed successively with dilute sulfuric acid, Na 2 CO 3 solution, and water, dried, and evaporated. After purification by chromatography over silica gel, 3,18-bis(heptanoyloxy)-17 ⁇ -ethinyl-1,3,5(10)-estratrien-17 ⁇ -ol is produced.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Steroid Compounds (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=5887233

Family Applications (1)

Country Status (10)

Cited By (7)

Families Citing this family (2)

Citations (2)

• 1973
  • 1973-07-13 DE DE19732336432 patent/DE2336432A1/de active Pending
• 1974
  • 1974-07-09 DK DK367774A patent/DK133050C/da active
  • 1974-07-11 DD DD179872A patent/DD113754A5/xx unknown
  • 1974-07-12 NL NL7409497A patent/NL7409497A/xx not_active Application Discontinuation
  • 1974-07-12 US US05/487,969 patent/US3960841A/en not_active Expired - Lifetime
  • 1974-07-12 JP JP49080115A patent/JPS5047966A/ja active Pending
  • 1974-07-12 CH CH964474A patent/CH609706A5/xx not_active IP Right Cessation
  • 1974-07-12 BE BE146507A patent/BE817596A/xx unknown
  • 1974-07-15 GB GB31240/74A patent/GB1479362A/en not_active Expired
  • 1974-07-15 FR FR7424500A patent/FR2236506B1/fr not_active Expired

Patent Citations (2)

Non-Patent Citations (3)

Also Published As

Similar Documents